London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Maybe a little upward movement on the cards?
And back to sleep!
Excellent day. Who was it complained that Amryt was boring recently? Quality company making great products. LT hold for me.
GLA DJF
Nice chunk at £2 ..
I think we have consolidated for long enough
Excellent RNS from Amryt this morning.
Approval from NICE for Myalepta is a major step forward in Amryt's European marketing strategy for this drug and means that they've now secured reimbursement in UK, Italy and Germany as well as the US, Japan and Turkey. Applications are being considered in several other European countries too, so hopefully more to come. Myalepta (called Myalept in the US) is the 5th most expensive drug in the world so every new reimbursement approval is significant.
'Myalept Produced by the international Amryt Pharma, Myalept treats generalized lipodystrophy, a condition that removes virtually all the fat from a person’s body affecting the production of leptins — a hormone in the small intestine that helps regulate energy levels and determines hunger. It comes in a powder form, and is meant to be mixed with sterile water for each dose. Just one of these doses costs $6,412 which, at the necessary 30 doses a month, adds up to $192,335.'
Possible/likely that NICE have secured a discount for the NHS, nevertheless the total cost of just under $200k above is each and every month and patients remain on treatment for years.
https://www.healthing.ca/pharma/the-worlds-10-most-expensive-drugs
Wow what a lad to do that. !
nomoneyman,
Excellent thanks for posting
https://www.dailymail.co.uk/money/investing/article-9106815/Our-share-tips-New-Year-lets-hope-better-one.html
Alex Lawson, Senior City Correspondent
Amryt Pharma: Irish biotechnology firm Amryt has seen its share price double since March as investors piled into pharmaceutical stocks amid the Covid crisis. That trend shows little sign of abating. Amryt develops treatments for rare diseases and is trying to tackle 'butterfly skin' conditions, where the skin blisters easily.
It is awaiting regulatory approval for a promising cream that accelerates wound healing and reduces itching, and has just won US state support to study the genetics of the cause of the condition.
The company, listed on AIM in the UK and Nasdaq in America, recently raised $40million (£30million) in a share placing, so has the firepower to invest for growth. Its shares are currently at £1.89, valuing it at £335million. Far from a safe bet, but a promising prospect.
This stock is an enigma..
No idea why this is not showing on LSE but more good news this morning.
AMRYT PHARMA PLC
Released 07:00:00 23 December 2020
Amryt Granted Orphan Drug Designation by the FDA for AP103
DUBLIN, Ireland, and Boston MA, December 23, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, is pleased to announce today that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for AP103 for the treatment of Dystrophic Epidermolysis Bullosa ("DEB"). AP103 is based on Amryt's gene-therapy platform technology and offers a potential treatment for patients with DEB, a subset of EB.
The FDA’s Office of Orphan Products Development (“OOPD”) grants orphan drug designation to support the development of medicines for rare diseases, that affect fewer than 200,000 people in the United States. Orphan drug designation may allow Amryt to be eligible for a seven-year period of U.S. Marketing exclusivity upon approval of AP103 and a waiver of the Prescription Drug User Fee Act (“PDUFA”) filing fees, subject to certain conditions.
AP103 is based on a new gene therapy delivery platform, in-licensed by Amryt in March 2018, that utilises a non-viral delivery vector, HPAE (Highly Branched Poly ß-Amino Ester), designed to deliver the correct collagen VII gene into skin cells.
Joe Wiley, CEO of Amryt Pharma, commented: "Receiving an orphan drug designation from the FDA for our gene-therapy candidate, AP103, is a significant development for patients suffering from EB and provides additional momentum to our development pipeline. Unlike other gene therapies that rely on viral vectors, AP103 is based on a novel polymer-based topical delivery platform, which we believe offers potential advantages in the gene-therapy field and has potential to be used in other genetic skin conditions.”
for Lojuxta..
I think Rory said a good while back that there are more cases of HOFH in the middle east (passed down hereidity,because of inter family marriages) than anywhere else in the world..
Is saying that something is happening.
He had to contain his excitement.
Next year, next year, around this time, this share will be multiples higher than its current level.
Very much sounds like it.
Increase liquidity..Really Joe?
That said I think they've got their eye on something..
Interview with Joe Wiley below
https://www.youtube.com/watch?v=kutZbMQ_i0s
It does seem like everything done at Amryt is at a snail's pace..
Someone tell Warren Buffet (:
That’s what it is.
Its might be construed that the current institutions know a good thing but I'd like to have seen new money get involved.
Maybe something big in the pipeline and they are being rewarded for their loyalty..
A capital raise wasn't on my radar as we know if Filsuvez gets FDA approval well bet the priority review voucher or $100.
Bronx, if all my shares were as boring as this one, I'd be a rich man. 50% average up and CVR's to come hopefully.
Amazing..still a yawn..
I guess boring is good but this stock takes the biscuit...
Yes that's correct
Agrred that seems most likely. Not sure of the timescales for settling the contingent rights - I think I read they can pay out cash or shares?
Interesting, just a couple of months ago they had a cash balance of over $75m with predicted revenue this year of around $180m. Can only think of one reason why they'd want to raise at this stage, they must surely be looking at another acquisition.
Spread is tightening..hard to know volume is nada..